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An engineered vascular endothelial growth
factor-activating transcription factor induces
therapeutic angiogenesis in ApoE knockout mice
with hindlimb ischemia
Donghua Xie, MD, PhD,a Yongjun Li, MD, PhD,a Erika A. Reed,a Shelley I. Odronic,a
Christopher D. Kontos, MD,a and Brian H. Annex, MD,a,b Durham, NC
Objective: Angiogenesis is the growth and proliferation of blood vessels from existing vascular structures, and therapeutic
angiogenesis seeks to promote blood vessel growth to improve tissue perfusion. Vascular endothelial growth factor
(VEGF) is a prototypic angiogenic agent that exists in vivo in multiple isoforms, and studies with VEGF to date had
used single isoform therapy with disappointing results. We tested plasmid and adenoviral vectors encoding a
zinc-finger DNA-binding transcription factor (ZFP-32E) that was designed to increase the expression of all major
VEGF isoforms in a preclinical model of peripheral arterial obstructive disease (PAOD) in hypercholesterolemic (ApoE
knock-out) mice.
Methods: Unilateral femoral artery ligation/excision was performed in 117 mice. At 7 days postoperatively, the ischemic
tibialis anterior (TA) and gastrocnemius (GAS) muscles received either ZFP-32E treatment (125 g of plasmid, 2.5 
1011 viral particle units [vpu] of adenovirus; some mice received a second plasmid injection 3 days later) or no-ZFP
treatment (125 g of -galactosidase [-gal], a plasmid-lacking insert, or an equal dose of adenoviral encoding -gal;
some mice received a second plasmid injection 3 days later). Group 1 mice (n  31) were euthanized 3 days later, and
VEGF messenger RNA (mRNA) and protein levels were measured. Group 2 mice (n 38) were euthanized 7 days later,
and measures of capillary density, cell proliferation, and apoptosis were quantified. Group 3 mice (n  48) were
euthanized 28 days later, and changes in lower limb blood flow perfusion were measured.
Results: In group 1, VEGFmRNA and protein levels were significantly higher in those with ZFP-32E treatment vs -gal.
In group 2, capillary density and proliferating cells were significantly greater and apoptosis was significantly lower in
those with ZFP-32E treatment vs -gal. Finally, in group 3, changes in the perfusion ratio (ischemic/nonischemic limb)
at 21 days after injection were significantly greater in those with ZFP-32E treatment vs no-ZFP treatment.
Conclusion: The ability of this engineered zinc-finger VEGF-activating transcription factor to induce therapeutic
angiogenesis in hypercholesterolemic mice suggests this approach warrants investigation as a novel approach to treat
PAOD. (J Vasc Surg 2006;44:166-75.)
Clinical Relevance: Therapeutic angiogenesis is an investigational method that seeks to promote the growth of blood
vessels for the treatment of disorders of inadequate tissue perfusion. Patients with peripheral arterial occlusive disease
(PAOD) are a major target population. This study used a novel approach to increase endogenous expression of vascular
endothelial growth factor in a preclinical model of PAOD, where the capacity to induce therapeutic angiogenesis is known
to be very difficult. This approach demonstrated beneficial effects in this model and will serve as a valuable link to advance
this and related approaches, toward human investigation.Peripheral arterial obstructive disease (PAOD) is a ma-
jor health care problem in the United States. The age-
adjusted prevalence of PAOD is 12%, and the prevalence of
PAOD can be expected to increase because of the aging
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166population.1-3 Intermittent claudication and critical limb
ischemia are the two major clinical manifestations of
PAOD. The primary pathophysiology of PAOD is obstruc-
tive atherosclerosis leading to impaired perfusion in the
lower extremities.
Medical treatments in patients with PAOD have been
directed toward modifying the underlying pathophysio-
logic etiologies, but no current medical therapies in PAOD
are able to increase blood flow to the ischemic limb.4,5
Surgical and, increasingly, percutaneous revascularization
strategies are used improve blood flow in selected patients.
However, a sizeable fraction of patients with PAOD, and
especially those with critical limb ischemia, are not eligible
for surgery owing to poor conduits or suitable recipient
targets, have significant comorbidities making them poor
candidates for revascularization, or have secondary compli-
us; PL
ection
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patency.1,6 Clearly, new primary and adjunctive treatments
are needed for these patients.
Angiogenesis is the growth and development of new
capillaries from a pre-exiting vasculature, and therapeutic
angiogenesis seeks to harness this phenomenon for the
treatment of disorders of inadequate tissue perfusion.7,8
Vascular endothelial growth factor (VEGF) is a prototypic
angiogenic growth factor that exists in at least four splice
variants with lengths from 121 to 206 amino acids.9 Results
from placebo-controlled trials that used a single VEGF
isoform in patients with coronary artery and PAOD have
been disappointing.10,11
Regulation of endogenous VEGF transcription is one
method to simultaneously modulate levels of multiple
VEGF isoforms. Mammalian genomic DNA contains bind-
ing sites for many proteins, including zinc-finger transcrip-
tion factors. Zinc-finger DNA-binding protein (ZFP) sites
are found in a number of genes, including the VEGF gene,
and these domains frequently serve as sites for the binding
of transcription factors that regulate gene expression in
vivo.12-13 ZFP transcription factors can be designed to bind
specific DNA sequences, and by the fusion of the binding
domain to a transcriptional enhancer or repressor, these
artificial ZFPs can increase or decrease gene expression.12
Rebar et al13 showed that an engineered ZFP linked to a
transcriptional activation domain was able to bind upstream
of the VEGF gene, increase VEGF gene expression in
normal mouse skeletal muscle, and induce angiogenesis in a
mouse ear angiogenesis model.
In a rabbit model of PAOD, we demonstrated that
this ZFP transcription factor could increase the expression
of all VEGF isoforms and favorably modulate the angio-
genic response to hindlimb ischemia.14 However, in the
rabbit model of PAOD, it is easy to promote angiogene-
sis.15 The apolipoprotein E (ApoE) gene encodes a 34-kDa
glycoprotein that coats many forms of circulating choles-
terol and then serves as a high-affinity ligand for receptors
that facilitate the removal of the coated particles from the
Table. Description of study and group assignments
Group 1 (n  31) Group
Harvesting at day 3 postinjection; total
duration of ischemia, 10 days
Harvesting at day
duration o
VEGF expression Histology
Group Group
1C (n  6): One dose ZFP-32E AV 2D (n  6): 1 d
1B (n  12): One dose ZFP-32E PL 2C (n  9): 2 d
1A (n  13): No-ZFP treatment 2B (n  5): 1 d
1 dose Pvax (n  4) 2A (n  18): N
1 dose -gal (n  5) 1 dose -gal
1 dose -gal AV (n  4) 2 doses -gal
1 dose -gal
ZFP-32E, Zinc-finger DNA-binding transcription factor 32E; AV, adenovir
All mice received injection of materials at day 7 of ischemia. The amount of injcirculation. ApoE knock out (/) mice have a limited abil-ity to promote angiogenesis after hindlimb ischemia.15,16
We therefore sought to evaluate this engineered VEGF-
activating ZFP transcription factor in a preclinical model of
PAOD in ApoE/mice fed a high cholesterol diet before
and during the postoperative and post-treatment period.
MATERIAL AND METHODS
Plasmid DNA constructs and formulations. VEGF-
activating ZFP and controls, previously described, were
provided in adenoviral and plasmid vectors by Edwards
Lifesciences (Irvine, Calif).13 Briefly, the plasmid contains
the coding sequence for three ZFP DNA binding sites, the
nuclear translocation signal from SV40 large T antigen, and
the transactivation domain from the p65 subunit of the
human nuclear factor (NF)-kB, subcloned into pVAX1
(Invitrogen, Carlsbad, Calif) with expression under direc-
tion of the cytomegalovirus (CMV) promoter. In prior
studies, this artificial transcription factor was shown to bind
genomic DNA and increase VEGF-A transcription.13 The
only other angiogenic growth factor shown to be increased
was VEGF-D, and that was at a lower level then VEGF-A.13
An identical plasmid lacking the ZFP insert, a plasmid and
adenovirus encoding the -galactosidase (-gal) gene were
provided in identically appearing, coded vials. Blinding was
maintained until data analysis was complete.
Hindlimb ischemia model and treatment group
assignments. A total of 117 ApoE/mice (Jackson Lab-
oratory, Bar Harbor, Maine) were obtained at 8 weeks of
age, fed a 1.25% cholesterol diet for 4 weeks, underwent
surgically induced unilateral hindlimb ischemia, and were
fed the same diet for the entire study.
Before surgery, mice received intraperitoneal injections
of ketamine (50 mg/kg) and xylazine (5 mg/kg). An
incision was made along the left medial thigh to allow
isolation, ligation, and excision of the femoral artery from
its origin just above the inguinal ligament to its bifurcation
at the origin of the saphenous and popliteal arteries.14 The
inferior epigastric, deep femoral, lateral circumflex, and
superficial epigastric arteries were also isolated and ligated.
38) Group 3 (n  48)
stinjection; total
emia, 14 days
Harvesting at day 28 postinjection; total
duration of ischemia, 35 days
Blood flow measurement at day 7, 14,
21, and 28
Group
FP-32E AV 3D (n  9): 1 dose ZFP-32E AV
ZFP-32E PL 3C (n  9): 2 doses ZFP-32E PL
FP-32E PL 3B (n  9): 1 dose ZFP-32E PL
P treatment 3A (n  21): No-ZFP treatment
 5) 1 dose -gal PL (n  9)
n  7) 2 doses -gal PL (n  6)
 6) 1 dose -gal AV (n  6)
, plasmid.
material totalled 0.125 mL (125 g for plasmid, or 2.5 1011 vpu for virus).2 (n 
7 po
f isch
ose Z
oses
ose Z
o-ZF
PL (n
PL (
AV (nThe incision was closed. All animals were closely monitored
vs -gal. **P  .01 vs -gal.
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performed all of the procedures.
After 7 days of ischemia, the mice were anesthetized
with ketamine and xylazine. Bilateral hind-limb perfusion
measures were performed (described in a subsequent para-
graph), and the mice were randomly divided into ZFP
treatment or no ZFP treatment arms. Group treatment
assignments and study termination times were made to
accomplish different objectives.
Using a 27.5-gauge needle, gene transfer was accom-
plished by three 15-second intramuscular injections (total,
0.125 mL) across the tibialis anterior (TA) and gastrocne-
mius (GAS) muscle belly. The study was completed 3
(group 1, n  31), 7 (group 2, n  38), or 28 days later
(group 3, n  48) (Table). One or two doses of ZFP-32E
plasmid (125 g) or 2.5  1011 viral particle units (vpu)
(the ratio of vpu to plaque forming units was 100:1) of
adenovirus encoding ZFP-32E were administered. Where
applicable, a second plasmid dose was administered 3 days
after the first dose. A plasmid (PL) encoding -galactosidase
(-gal PL, 125 g), an “empty” plasmid with no insert
(p-Vax PL, 125 g), 2 doses (-gal PL, 125 g/dose), or
one dose adenovirus (AV) encoding -gal (-gal AV, 2.5
1011 vpu) was used. A single operator (D.H. X.) performed
all of the treatments.
All protocols and procedures conformed with the
Guidelines for Use of Laboratory Animals published by the
United States Department of Health and Human Services
and were approved by the Duke University Animal Care
and Use Committee. All animals received care in accor-
dance with Principles of Laboratory Animal Care, formu-
lated by the National Society for Medical Research, and
Guide for the Care and Use of Laboratory Animals, pub-
lished by the National Institutes of Health (NIH Publica-
tion No. 86-23, revised 1985).
Tissue procurement, histological section, mRNA ,
and protein preparation. Tissue harvests were performed
at the study’s termination. Bilateral hindlimb perfusion
measures were performed after light anesthesia with ket-
amine and xylazine. Additional anesthetic was then given,
and the ischemic and contralateral TA and GAS muscles
were surgically excised from tendon to tendon. Mice were
then euthanized using intravenous phenobarbital (150
mg/kg) and phenytoin sodium (25 mg/kg).
The mid portion of the muscle was placed in 30%
sucrose-phosphate-buffered saline solution, mounted, and
frozen cryostat sections (5m)were prepared. The remain-
der was snap frozen in liquid nitrogen. RNA extracts and
protein lysates were made and concentrations were deter-
mined using methods previously described.14
Quantification of VEGF mRNA and protein in
skeletal muscle. RNA was treated with DNase, repurified,
and 1 g was used for first-strand complimentary DNA
(cDNA) synthesis by reverse transcription using methods
previously described.14 The cDNA products (50 ng) were
amplified by quantitative TaqMan real-time reverse transcrip-
tase polymerase chain reaction (PCR) using TaqManUniver-
sal PCR Master Mix kit and the manufacturer’s instructionsFig 1. A, Vascular endothelial growth factor (VEGF) messenger
RNA copy number (ischemic limb minus nonischemic limb for
each animal) and protein expression is shown from group 1 mice,
which were injected 7 days after the induction of hindlimb isch-
emia. Tibialis anterior (TA) and gastrocnemius (GAS)muscle was
harvested 3 days after injection. The plasmid studies were per-
formed on the active agent zinc-finger DNA-binding transcription
factor 32E plasmid (ZFP-32E PL), a plasmid with the same back-
bone but no insert (P-Vax PL), and a nuclear localizing -
galactosidase (-gal PL), but statistical comparisons were done
using the ZFP-32E PL vs -gal PL. ELISA, Enzyme-linked immu-
noabsorbent assay. B, Bar graphs show mean standard deviation
of value to show the differences ZFP-32E PL vs -Gal PL and
ZFP-32E adenovirus (AV) vs -gal AV. TRT-PCR, TaqMan
real-time reverse transcriptase polymerase chain reaction. *P .05
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performed using VEGF-A and 18S specific primers (forward
5=-TACTGCTGTACCTCCACCTCCACCATG-3= and re-
verse TCACTTCATGGGACTTCTGCTCT, and forward
5=-CGGCTACCACATCCAAGGAA-3= and 5=-AGCCGC-
GGTAATTCCAGC-3,= respectively) and probes (5=-AAGT-
GGTCCCAGGCTGCACCCAC-3= and 5=-TGCTGGCAC-
CAGACTTGCCCTC-3,= respectively).A sequence detector continuously measured the ampli-
fied product in direct proportion to the increase in fluores-
cence, captured the signal, and an amplification plot was
generated.14 A threshold cycle (Ct) representing the PCR
cycle number at which the fluorescence was detectable
above threshold was calculated. Final mRNA concentra-
tions were calculated using the Ct value, normalized for
18S ribosomal RNA. Negative controls lacking template
RNA were always included, and samples were tested in
triplicate. Total VEGF protein concentrations were deter-
mined by a solid-state enzyme linked immunoassay system,
as previously described.14
Capillary density, proliferation, and apoptosis in
skeletal muscle. Capillary density (capillaries/mm2 and
capillaries/fiber) was measured by counting six random high-
power (100 magnification) fields from endogenous endo-
thelial alkaline phosphatase staining, as described. 13,17,18 Dig-
ital images were captured using an inverted light microscope,
analog camera, Adobe Premier (Adobe Systems, San Jose,
Calif), a hemocytometer for area measurements, and an NIH
image analysis system, as described.13,18
Immunohistochemistry was performed using methods
previously described.17-19 CD-31 endothelial cell antibody
(Santa Cruz Biotechnology, Calif) was used at 2 g/mL,
4 °C overnight. A mouse monoclonal anti-human prolifer-
ating cell nuclear antigen (PCNA) antibody (Santa Cruz
Biotechnology, Santa Cruz, Calif) was used at 2 g/mL,
room temperature 1 hour. An in situ terminal deoxynucleo-
tidyl transferase (TdT) biotin-dUTP nick-end labeling
(TUNEL) apoptosis kit, ApopTag (Intergen Company,
Purchase, NY), was used to label apoptotic cells, as de-
scribed.14 Positive control slides included pretreatment
with DNase I (Sigma, St Louis, Mo) and negative controls
were performed without active TdT. The proliferation and
apoptotic index were expressed as a percentage of positive,
divided by the total number of nuclei, on three randomly
selected 200x (200 nuclei/sample) fields. Apoptosis was
also measured as positive nuclei/mm2. A blinded single
reader performed all the analyses. The variability on repeat
measures was 10%.
Hemodynamic assessment. Bilateral hindlimb perfu-
sion was measured using PERISACN System blood perfu-
sion monitor laser Doppler equipment (PERIMED, Stock-
Fig 2. A, Representative alkaline phosphatase stains show that
capillary density in the ischemic skeletal muscle treated with the
zinc-finger DNA-binding transcription factor 32E (ZFP-32E) ad-
enovirus (AV) is higher than (B) in muscle treated with -
galactosidase (-gal) AV at 7 days after injection. Dark blue dots
indicate capillaries (100 original magnification, CD-31 staining).
C,The table shows the quantitative data of the two complimentary
measures of vascular density. Note that the alkaline phosphatase
data were analyzed as both capillaries/mm2 as well as capillaries per
fiber. The CD-31 data were analyzed as percent positive nuclei.
Symptoms show the P values for the t tests of the individual ZFP
regimen to the matched -gal regimen. TA,Tibialis anterior;GAS,
gastrocnemius.
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Based upon the group assignments (Table), blood flow was
measured at preinjection (7 days after ligation) and again at
7, 14, 21, and 28 days postinjection, which corresponded
to a total of 14, 21, 28, 35 days of ischemia. Calculated
perfusion was expressed as a ratio of left (ischemic) to right
(normal) limb. Changes in the perfusion ratio were ob-
tained by subtracting the perfusion ratio at day 7 from the
ratio obtained on the day of the study.
Statistical analysis. Unless otherwise stated, results
were expressed asmean standarddeviation. ForZFP-VEGF
vs -gal at one time point, statistical significance was eval-
uated by use of Student’s t test. P  .05 was considered
significant. To determine the effects of ZFP-VEGF vs -gal
on the changes in perfusion over time, a standard analysis of
variance (ANOVA) repeated measures was performed.
RESULTS
ZFP-VEGF increased VEGF mRNA and protein in
ischemic muscle. We first sought to determine whether
the ZFP-VEGF plasmid or ZFP-VEGF adenovirus were
able to increase the expression of VEGFmRNA and protein
in the ischemic limb compared with -gal plasmid or ade-
novirus. For the plasmid arm, an additional regimen was
the delivery of the empty plasmid (p-Vax). Thirty-one mice
Fig 3. Graphic representation of the quantitative assess
tase and CD31 staining, in the ischemic and nonischem
Panels A and C are of the tibialis anterior (TA) muscle
panels, values in the nonischemic limb were similar. Be
similar, they were combined for this graph. Statistical com
a single dose of plasmid vs a single dose of plasmid). ZFP-
adenovirus; PL, plasmid. *P  .05. **P  .01.were harvested on day 3 postinjection (total of 10 days ofischemia). This ZFP plasmid dose was 25% of the dose that
was therapeutically effective in rabbits.12 The adenoviral
dose was approximately one-log greater than the in vivo
dose used in immunocompromised mice.13 This was se-
lected as a time when the plasmid was expected to be
expressed but before changes in muscle blood flow would
occur, since changes in blood flow could influence VEGF
expression. The mRNA copy numbers were expressed as
ischemic limb minus the nonischemic limb for each animal.
The results are shown numerically in Fig 1, A and graphi-
cally in Fig 1, B.
Overall, both the plasmid and adenovirus increased
VEGF mRNA and protein expression in TA and GAS
muscles. For the plasmid studies, the VEGF expression in
the -gal plasmid was higher than p-Vax, and only statisti-
cal comparisons against the -gal plasmid were performed.
Taken together, these data suggest that the ZFP-VEGFwas
able to increase VEGF mRNA and protein expression in
ischemic skeletal muscle, and the -gal was used as the
regimen control in all future groups.
ZFP-VEGF modulates vascular density, prolifera-
tion, and apoptosis. Next, we sought to determine whether
increases in VEGF expression were followed by an increase
in vascular density in ischemic skeletal muscle 7 days after
gene transfer (14 days of total ischemia). Representative
s of vascular density performed by the alkaline phospha-
mbs from the different treatment groups, respectively.
B and D are of the gastrocnemius (GAS) muscle. In all
values amongst the -galactosidase groups were very
ons were done in a manner identical to those in Fig 2 (ie,
Zinc-finger DNA-binding transcription factor 32E;AV,ment
ic li
and,
cause
paris
32E,examples of alkaline phosphatase staining are shown at the
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alkaline phosphatase staining and quantified as capillaries/
mm2, capillaries/fiber, or by immunohistochemistry, each
ZFP-VEGF regimen was superior to the identical -galregimen. The results of the quantitative assessments and
statistical comparisons are shown on the bottom of Fig 2.
The results are then shown graphically in Fig 3, where it is
visually apparent that the adenovirus was virtually identical
to the two doses of plasmid.
We then sought to determine whether changes in cell
proliferation, cell death, or both, contributed to the
changes in vascular density in the ischemic muscle treated
with the ZFP-32E. A representative set of TUNEL stains
are shown on the top of Fig 4. The results of the quantita-
tive assessments and statistical comparisons are shown on
the bottom of Fig 4. Each ZFP-VEGF regimen was statis-
tically different from the identical -gal regimen, with
ZFP-VEGF treatment being associated with a decrease in
apoptosis and an increase in proliferation. Because mea-
sures expressed as a percentage of total nuclei that could
have been influenced by the number of nuclei per field, this
measure was made and found to be no different across the
treatment regimens. In addition, values within the -gal
regimens were quite similar, and therefore, these were
combined for the graphic display of the results in Fig 5.
Again, the adenovirus was virtually identical to the two
doses of plasmid.
ZFP-VEGF gene transfer improves limb perfusion
after hindlimb ischemia. Mice in group 3 underwent
blood flow measurements at day 7 postligation (immedi-
ately before gene transfer) and weekly at four additional
time points until euthanasia at day 28 postinjection. Data
are expressed as the ratio of signal in the ischemic limb
relative to the nonischemic limb.
Immediately before injection, the perfusion ratio for all
mice was 47.92% 5.2%, and there was no difference in the
baseline values for the ZFP-treatment vs -gal regimens.
Fig 6 shows the changes in the perfusion ratio from prein-
jection (time point 1) every week for 4 weeks, shown as
time points 2 to 5. The ANOVA repeated measures analysis
addressed whether ZFP-32E was superior to -gal and
whether the treatment effect was getting better over time.
In the top panel, one dose of the ZFP-32E plasmid (PL)
was superior to one dose of the -gal plasmid (PL) by 7.7%
(P  .004), and one dose of the ZFP-32E plasmid (PL)
became significantly greater over time compared with one
dose of the -gal plasmid (P  .009). In the middle panel,
Fig 4. A, Representative examples of terminal deoxynucleotidyl
transferase (TdT) biotin-dUTP nick-end labeling (TUNEL) stain-
ing from zinc-finger DNA-binding transcription factor 32E (ZFP-
32E) adenovirus (AV) treatment (top) and a -galactosidase (-
gal) AV treatment (bottom) at 7 days after injection. TUNEL-
positive nuclei (brown color, arrows) are visible in the ischemic
muscle from both groups, but the number of apoptotic cells in the
ZFP-32E treated arm is much lower than in the -gal treatment
(200 original magnification). B,Quantitative assessments of the
extent of apoptosis are expressed both as the fraction of positive
nuclei and the number of TUNEL	 nuclei per unit area. The level
of significance for the paired t test of the treatment vs no-treatment
are shown and labeled below.
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two doses of the -gal plasmid (PL) by 11.2% (P  .001),
and two doses of the ZFP-32E plasmid (PL) became sig-
nificantly greater over time compared with two dose of
the -gal plasmid (P  .001). In the bottom panel, one
dose of the ZFP-32E adenovirus (AV) was superior to one
dose of the -gal adenovirus (AV) by 12.3% (P  .001),
and one dose of the ZFP-32E adenovirus (AV) became
significantly greater over time compared with one dose of
the -gal adenovirus (P .001). The relatively small num-
bers per group did not permit comparison between the
ZFP-VEGF treatment groups.
DISCUSSION
Therapeutic angiogenesis remains an investigative ap-
proach to attempt to improve limb perfusion and clinical
Fig 5. Graphic representation of the quantitative asse
nonischemic limbs from the different treatment gro
Gastrocnemius (GAS) muscle. In all panels, values in
amongst the -galactosidase groups were very similar
graph. Statistical comparisons were done in amanner iden
dose plasmid). ZFP-32E, Zinc-finger DNA-binding trans
respectively.outcomes in patients with established PAOD. In this study,we used a preclinical model of PAOD to evaluate the effects
of an intramuscular injection(s) of a transcription factor
designed to bind to the regulatory region of the VEGF
gene in hypercholesterolemic mice on a high cholesterol
diet. There were several notable findings:
1. The ZFP-VEGF transcription factor given by either a
plasmid or an adenovirus led to an upregulation of
VEGF protein and mRNA in glycolytic (TA) and oxi-
dative (GAS) ischemic skeletal muscle.
2. Treatment with the ZFP-VEGF led to an increase in
capillary density, an increase in cellular proliferation,
and a reduction in apoptosis in the ischemic mus-
cles.
3. There was evidence of therapeutic angiogenesis, with an
increase in perfusion to the ischemic limb in the ZFP-
nts of proliferation and apoptosis in the ischemic and
A and C, Tibialis anterior (TA) muscle. B and D,
nonischemic limb were quite similar. Because values
in some cases identical, they were combined for this
to those in Fig 2 (ie, a single dose plasmid against a single
ion factor 32E; AV, adenovirus; PL, plasmid. **P  .01ssme
ups.
the
and
tical
criptVEGF treatment groups.
AV (P  .001). VEGF, Vascular endothelial growth factor.
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enous VEGF gene can lead to therapeutic angiogenesis in
this preclinical model, which is known to have a diminished
capacity for an angiogenic response to ischemia.
The inability to increase VEGF in the setting of isch-
emia has been reported in ApoE/ mice.20,21 Because
endogenous and artificial ZFP transcription factors work
though binding to specific regions in the genome and other
transcription factors or proteins could have been present
and bound in the regulatory portion of the VEGF gene in
these ischemic skeletal muscle, we first sought to establish
that the ZFP-VEGF could increase endogenous VEGF
gene expression. These data support our previous study14
in rabbits fed normal chow, where we showed the ZFP-
VEGF-activating transcription factor was able to increase
endogenous VEGF gene expression and all VEGF-A iso-
forms in ischemic peripheral skeletal muscle. Studies in
these two very different PAOD models provide support
that that this artificial ZFP will eventually be able to in-
crease VEGF expression in the ischemic muscle of patients
with PAOD.
We previously demonstrated that hindlimb ischemia in
rabbits results in a decrease in proliferation and an increase
in apoptosis in ischemic muscle at the 7 day time point after
ligation.22 In group 2 at that same time point in our current
study in hypercholesterolemic mice, we found that treat-
ment of ischemic muscle with the ZFP-VEGF-activating
transcription factor resulted in an increase in PCNA-positive
cells, along with a decrease in apoptotic cells.
VEGF has been shown to act as a survival factor to
protect endothelial cells from cell death.23 Germani et al24
showed that ex vivo treatment of myoblasts with a
VEGF165 adenovirus reduced apoptosis in vitro, and in a
mouse hindlimb model, pretreatment with intramuscular
adeno-VEGF165 injection reduced apoptosis in muscle af-
ter ligation. Reductions in apoptosis in ischemic muscle
may beneficial to patients, but the translation of this finding
to clinic outcomes remains speculative.
Finally we sought to determine whether the ZFP-VEGF
treatment would lead to improvements in limb blood flow
compared with -gal. We found evidence for a treatment
effect from the ZFP-VEGF irrespective of the dosing regi-
men, and although the ZFP-32E adenovirus virus and the
two doses of plasmid appeared to have greater efficacy than
the single dose of plasmid, the number of mice needed to
test a statistical difference would be quite large. Couffinhal
et al20 found that treatment of ApoE/ mice with a
hindlimb model using adeno-VEGF165 led to increases in
blood flow; however, these changes were not evident until
28 days after gene transfer, whereas our time course sug-
gested an earlier response. When combined with other data
demonstrating advantages of delivery of multiple over sin-
gle VEGF isorforms, our data provide additional evidence
that the delivery of multiple isoforms may be preferable
when the capacity to produce an angiogenic response is
low, although validation can only be achieved throughFig 6. The three panels show the changes in the perfusion ratios
over time for each zinc-finger DNA-binding transcription factor
(ZFP) treatment vs  galactosidase (-gal) control. Time point 1
represents the value before injection of the agent or -gal control,
time point 2 is 7 days after injection, time point 3 is 14 days after,
time point 4 is 21 days after, and time point 5 is 28 days after
injection. Data were analyzed using a standard ANOVA repeated
measures analysis. In the top panel, 1 dose of the ZFP-32E plasmid
(PL)was superior to 1 dose of the -gal PL by 7.7% (P .004) and
1 dose of the ZFP-32E PL became significantly greater over time
compared to 1 dose of the -gal plasmid (P .009). In the middle
panel, 2 doses of the ZFP-32E PL was superior to 2 doses of the
-gal PL by 11.2% (P  .001), and 2 doses of the ZFP-32E PL
became significantly greater over time compared with 2 doses of
the -gal PL (P  .001). In the bottom panel, 1 dose of the
ZFP-32E adenovirus (AV) was superior to 1 dose of the -gal AV
by 12.3% (P  .001), and 1 dose of the ZFP-32E AV became
significantly greater over time compared with 1 dose of the -galhuman investigation.
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challenges that exist in moving the findings from preclinical
studies into clinical investigation. Although in prior studies
we used a series of controls for the ZFP-VEGF treatment,
including sham injections, saline, and poloxamer delivery,
we almost exclusively used -gal in this current study. This
was selected over the empty plasmid, which had a slightly
lower VEGF expression. Reduced inflammation may be
mechanism by which hypercholesterolemic mice have an
impaired angiogenic response to hindlimb ischemia,16 and
therefore, the selection of -gal, if anything, should have
reduced our ability to detect a treatment effect. Interest-
ingly, we found no significant difference between the plas-
mid and adenovirus in regards to total nuclei per area of
tissue, which at least indirectly suggests no change in in-
flammation at that one time point.
Viral vectors have been utilized with success more
frequently than any other method of gene delivery in
animal models.25 Viral vectors have better levels of ex-
pression than those achieved by DNA plasmid vector,26
although we were able to obtain similar short and long-
term effects with two doses of plasmid separated by 3
days. Potential advantages to plasmid delivery also in-
clude the ability to repeat dosing without the concern of
antibody generation.27 In addition, the shorter dura-
tions of expression that occur with the adenovirus com-
pared with the plasmid may be advantageous in situa-
tions where toxicity is a concern.28 In cell culture, ZFP
transcription factors can be designed to target unique
sites in the genome and thus regulate the intended target
gene, and no other.29
CONCLUSION
In our current study we did not directly demonstrate
binding of the artificial ZFP, nor did we demonstrate
exclusive upregulation of VEGF-A. It is possible that this
specificity may not be maintained in vivo, but more likely,
in vivo multiple cells are transfected and changes in VEGF
induce direct and indirect effects on gene expression in
endothelial cells, myocytes, and other cells present in the
muscle. Therapeutic testing in humans must balance risks
and benefits; however, the results of this study suggest the
potential for using the ZFP-VEGF gene transfer to treat
PAOD, including patients with critical limb ischemia.
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